Jagadish Khanagavi
Interventional Cardiology · Cincinnati, OHNPI 1457669897
Payments from drug & device makers
Across 158 payments — averaging $60.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Penumbra, Inc.$3K
- Novartis$389
- Inari Medical, Inc.$378
- Abbott$358
- Abiomed$322
- plus $3K from 28 others
What the payments were for
- Travel & lodging$3,72239%
- Food & beverage$5,72760%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $3,027 |
| Penumbra, Inc. | 7 | $2,510 |
| Novartis | 20 | $389 |
| Inari Medical, Inc. | 4 | $378 |
| Abbott | 10 | $358 |
| Abiomed | 3 | $322 |
| Boston Scientific | 4 | $241 |
| Merck | 10 | $229 |
| Cardiovascular Systems Inc. | 3 | $204 |
| Imperative Care, Inc | 1 | $201 |
| Novo Nordisk | 9 | $188 |
| Johnson & Johnson | 5 | $173 |
| AstraZeneca | 10 | $159 |
| Teleflex LLC | 1 | $131 |
| Boehringer Ingelheim | 5 | $127 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $106 |
| Pfizer | 5 | $104 |
| Stryker | 1 | $98 |
| Medicomp Inc | 3 | $96 |
| Scpharmaceuticals Inc. | 4 | $77 |
| Bayer | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 2 | $65 |
| Livanova USA, Inc. | 2 | $37 |
| Baxter Healthcare | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Terumo Medical Corporation | 1 | $22 |
| Biotronik Inc. | 1 | $22 |
| Cleerly, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUBY Coil$2,097
- RESOLUTE ONYX$998
- SYMPLICITY G3$841
- Resolute$473
- Penumbra System$288
- PRODIGY CATHETER$201
- FlowTriever$182
- ClotTriever$182
- AVVIGO Guidance System$138
- Xience V coronary stent system$133
- Diamondback Coronary$132
- GUIDELINER$131
- Impella$130
- Indigo$125
- FLOWTRIEVER CATHETER, S$125
- CT THROMBECTOMY SYSTEM KIT$125
- COREVALVE EVOLUT R$120
- XARELTO$104
How this compares
$9,522 in reported general payments places this provider in the 55th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $50,996 |
| EntrestoSacubitril/Valsartan | 64 | $41,207 |
| JardianceEmpagliflozin | 25 | $17,554 |
| BrilintaTicagrelor | 21 | $10,994 |
| Metoprolol Succinate | 201 | $1,933 |
| Atorvastatin Calcium | 184 | $1,108 |
| Rosuvastatin Calcium | 55 | $932 |
| Valsartan | 41 | $840 |
| Ezetimibe | 45 | $775 |
| ClopidogrelClopidogrel Bisulfate | 80 | $679 |
| Ranolazine ErRanolazine | 12 | $520 |
| Carvedilol | 56 | $456 |
| Amlodipine Besylate | 118 | $411 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 51 | $350 |
| Lisinopril | 80 | $343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $50,99671 claims |
| NovartisEntresto | $389 | $41,20764 claims |
| Boehringer IngelheimJardiance | $127 | $17,55425 claims |
| AstraZenecaBrilinta | $159 | $10,99421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cincinnati
- Santiago GarciaCincinnati$3.6M
- Dean KereiakesCincinnati$3.4M
- Joseph ChooCincinnati$1.9M
- Timothy HenryCincinnati$1.3M
- John CorlCincinnati$793K
- Ian SarembockCincinnati$266K
- Puvi SeshiahCincinnati$230K
- Steven RudickCincinnati$216K
- Imran ArifCincinnati$127K
- Jonathan RappCincinnati$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.